Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | CSF1R | P07333 | 1/20 | 0.33 |
| ▸ | CDK4 | P11802 | 1/20 | 0.33 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25966721 | 0.89 | DRD2 (0.31) | DRD2HTR6 | |
| SCHEMBL24424398 | 0.88 | CSF1R (0.31) | CSF1RCDK4CDK6 | |
| SCHEMBL24156621 | 0.88 | CSF1R (0.31) | CSF1RCDK4CDK6 | |
| SCHEMBL25085441 | 0.85 | HRH4 (0.33) | CSF1RCDK4CDK6ROCK2ROCK1 | |
| SCHEMBL23594254 | 0.77 | GRM5 (0.34) | — | |
| SCHEMBL22381072 | 0.77 | KDM4E (0.35) | — | |
| SCHEMBL15293676 | 0.77 | HRH3 (0.31) | — | |
| SCHEMBL26805578 | 0.77 | — | — | |
| SCHEMBL25091013 | 0.76 | — | — | |
| SCHEMBL24253264 | 0.76 | CSF1R (0.33) | CSF1RCDK4CDK6ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230279012-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230250080-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LTD (GB) | 2023-08-10 | — | — | US | disclosed |
| US-20230250080-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LTD (GB) | 2023-08-10 | — | — | US | disclosed |
| US-11613527-B2 | Enzyme inhibitors | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2023-03-28 | — | — | US | disclosed |
| US-20230054782-A1 | BICYCLIC HETEROCYCLE COMPOUNDS METHODS OF USE THEREOF FOR THE TREATMENT OF HERPES VIRUSES | MERCK SHARP & DOHME LLC (US) | 2023-02-23 | — | — | US | disclosed |
| WO-2023281417-A1 | PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | GLENMARK SPECIALTY S.A. (CH) | 2023-01-12 | — | — | WO | disclosed |
| US-20220048894-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2022-02-17 | — | — | US | disclosed |
| US-11174252-B2 | Heterocyclic compounds as kinase inhibitors | NUVATION BIO INC. (US) | 2021-11-16 | — | — | US | disclosed |
| WO-2021127071-A1 | BICYCLIC HETEROCYCLE COMPOUNDS METHODS OF USE THEREOF FOR THE TREATMENT OF HERPES VIRUSES | MERCK SHARP & DOHME CORP. (US) | 2021-06-24 | — | — | WO | disclosed |
| US-10807994-B2 | Heterocyclic compounds and uses thereof | NUVATION BIO INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-9249123-B2 | Pyridinones/pyrazinones, method of making, and method of use thereof | GENENTECH, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-9238655-B2 | Heteroaryl pyridone and aza-pyridone compounds | GENENTECH, INC. (US) | 2016-01-19 | — | — | US | disclosed |
| US-8975260-B2 | Pyridazinones, method of making, and method of use thereof | GENETECH, INC (US) | 2015-03-10 | — | — | US | disclosed |
| US-8921353-B2 | Heteroaryl pyridone and aza-pyridone compounds | GENENTECH, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-20140378432-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH INC (US) | 2014-12-25 | — | — | US | disclosed |
| US-20140194408-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-8716274-B2 | Heteroaryl pyridone and aza-pyridone compounds | GENENTECH, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20130281432-A1 | PYRIDINONES/PYRAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GENENTECH, INC. (US) | 2013-10-24 | — | — | US | disclosed |
| US-20130261103-A1 | PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GENENTECH, INC. (US) | 2013-10-03 | — | — | US | disclosed |
| US-20130116235-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261103-A1 | PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | BTK, TYK2, LCK | DRD2 4608/4885HTR6 1865/4885CSF1R 1541/4885 |
| US-20230250080-A1 | ENZYME INHIBITORS | SERPINB1, KLKB1, SERPINE1 | DRD2 4189/4885HTR6 2721/4885CSF1R 1997/4885 |
| US-11613527-B2 | Enzyme inhibitors | SERPINB1, KLKB1, SERPINE1 | DRD2 4189/4885HTR6 2721/4885CSF1R 1997/4885 |
| US-11174252-B2 | Heterocyclic compounds as kinase inhibitors | CDK6, CDK4, CDK9 | DRD2 2728/4885HTR6 1743/4885CSF1R 3721/4885 |
| US-20130281432-A1 | PYRIDINONES/PYRAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | BTK, PDXK, TYK2 | DRD2 4654/4885HTR6 1920/4885CSF1R 1871/4885 |
| US-20220048894-A1 | ENZYME INHIBITORS | SERPINB1, KLKB1, SERPINE1 | DRD2 4189/4885HTR6 2721/4885CSF1R 1997/4885 |
| US-20230279012-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | PDXK, BTK, TYK2 | DRD2 3739/4885HTR6 1399/4885CSF1R 2550/4885 |
| US-20130116235-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | BTK, PDXK, TYK2 | DRD2 4192/4885HTR6 2183/4885CSF1R 2306/4885 |
| US-20140378432-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | PDXK, BTK, TYK2 | DRD2 3739/4885HTR6 1399/4885CSF1R 2550/4885 |
| US-10807994-B2 | Heterocyclic compounds and uses thereof | WEE1, WEE2, CCNE1 | DRD2 4697/4885HTR6 4529/4885CSF1R 3809/4885 |
| US-20140194408-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | BTK, PDXK, TYK2 | DRD2 4192/4885HTR6 2183/4885CSF1R 2306/4885 |
| US-20230054782-A1 | BICYCLIC HETEROCYCLE COMPOUNDS METHODS OF USE THEREOF FOR THE TREATMENT OF HERPES VIRUSES | ZC3HAV1, HDAC11, CXCR1 | DRD2 4733/4885HTR6 4496/4885CSF1R 2422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.